Academic
Oncology
Dr. Matthew M. Cooney, MD
|
|
Give Review
Matthew Cooney is an expert in the field of Oncology. He went to medical school at Case Western Reserve University School of Medicine. He received 1 awards: "Regional Top Doctor". Doctor Matthew M. Cooney, MD is also a published physician. He has 28 publication published. The most recent publication is: Incidence of hypercoagulable events after image-guided percutaneous cryoablation of renal tumors: a single-center experience. He is registered with Medicare and accepts Medicare payments.
Publications
- Incidence of hypercoagulable events after image-guided percutaneous cryoablation of Renal tumors: a single-center experience.
- A phase I study of MN-029 (denibulin), a novel vascular-disrupting agent, in patients with advanced solid tumors.
- A phase I study of rebeccamycin analog in combination with oxaliplatin in patients with refractory solid tumors.
- A phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases, in patients with metastatic renal cell Carcinoma.
- Toxicity of sunitinib plus bevacizumab in renal cell Carcinoma.
- Phase I trial of docetaxel given every 3 weeks and daily lenalidomide in patients with advanced solid tumors.
- A phase I study of sunitinib plus bevacizumab in advanced solid tumors.
- Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.
- High-grade transitional cell carcinoma and melanosis of urinary Bladder: case report and review of the literature.
- A phase II trial of fosbretabulin in advanced anaplastic thyroid Carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome.
- Phase I/II trial of 5-fluorouracil and a noncytotoxic dose level of suramin in patients with metastatic renal cell Carcinoma.
- Phase I trial of docetaxel and thalidomide: a regimen based on metronomic therapeutic principles.
- Complications from vascular disrupting agents and angiogenesis inhibitors: aberrant control of hemostasis and Thrombosis.
- Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker?
- Promise of new vascular-disrupting agents balanced with cardiac toxicity: is it time for oncologists to get to know their cardiologists?
- Promising Systemic therapy for renal cell carcinoma.
- Novel vascular targeting/disrupting agents: combretastatin A4 phosphate and related compounds.
- Novel agents for the treatment of advanced kidney Cancer.
- A medical oncologist's approach to immunotherapy for advanced Renal tumors: is nephrectomy indicated?
- Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced Cancer.
- Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine.
- Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial Cancer (E4802): a trial of the Eastern Cooperative Oncology Group.
- Drug insight: vascular disrupting agents and angiogenesis--novel approaches for drug deLivery.
- A phase IB clinical and pharmacokinetic study of the angiogenesis inhibitor SU5416 and paclitaxel in recurrent or metastatic Carcinoma of the head and neck.
- Phase II trial of thalidomide as maintenance therapy for extensive stage small cell lung Cancer after response to chemotherapy.
- A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients ...
- Supraclavicular lymphadenopathy: the spectrum of pathology and evaluation by fine-needle aspiration biopsy.
Schools
Case Western Reserve University School of Medicine
University Hospital Of Cleveland
Conditions Treated
- Acute Leukemia
- AdRenal Gland Cancer
- Anemia
- Bladder Cancer
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Pathway X Tiered Hosp/Ind Direct Access OH
- Anthem Blue Cross Blue Shield HMO
- Anthem Blue Cross Blue Shield PPO
- Blue Card PPO
- Blue Cross Blue Shield of Illinois PPO
- CHAMPVA
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Cofinity PPO
- Commercial Insurance Company
- CoreSource
- Coventry Health America PPO
- First Health (Coventry Health Care) PPO
- Golden Rule
- Medicare Advantage PFFS
- HealthSmart
- Choice Care PPO
- Mail Handlers Benefit Plan (MHBP)
- Medicaid
- Medical Mutual of Ohio POS
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Mutual of Omaha
- NGS CoreSource
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Awards
- Regional Top Doctor
Education
-
Case Western Reserve University - University Hospitals -
Case Western Reserve University School of Medicine
Hospital
-
University Hospitals Case Medical Center
Drug Facts
| NPI NUMBER | 1356360200 | |
| NPPES Provider LastName | COONEY | |
| NPPES Provider FirstName | MATTHEW | |
| NPPES Provider ZIPCode | 441061716 | |
| NPPES Provider State | OH | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 791.0 | |
| Distinct Opioid Count | 6.0 | |
| Opioid Claim Count | 139.0 | |
| Percent Opioid Claims | 17.57 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1356360200 |
| Last Name Of The Provider | COONEY |
| First Name Of The Provider | MATTHEW |
| View All |
Similar Doctors
|
Dr. Ramon V. Tiu, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Bernard J. Silver, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Alvin H. Schmaier, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Douglas W. Warden, MD |
|
|
Dr. Ernest C. Borden, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Debora S. Bruno, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Weifen Zeng, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Deepa Jagadeesh, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Pauline Funchain, MD |
|
Dr. Nathan Levitan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nathan A. Pennell, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Rami Manochakian, MD |
|
|
Dr. Jennifer L. Vollweiler, MD
This Doctor is OpenDoctor Recommended.
|